ArticleRadiation oncology (London, England)2022
Primary tumor volume and prognosis for patients with p16-positive and p16-negative oropharyngeal squamous cell carcinoma treated with radiation therapy.
Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- External Validation of Pre-Treatment Primary Tumor Volume as a Prognostic Factor in Head and Neck Cancer Treated With (Chemo)Radiotherapy.Head & neck · 2026Article
- Dosimetric comparison of lattice radiotherapy across three modern linear accelerator platforms.Precision radiation oncology · 2026Article
- The Impact of Tumor Volume Change Rate During Neoadjuvant Chemoradiotherapy-immunotherapy and of the Timing to Surgery on Prognosis in Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Study.Journal of gastrointestinal cancer · 2026Article
- Individualized VMAT lattice radiotherapy on a standard flattening-filter linear accelerator for advanced bulky tumors: a retrospective feasibility and early clinical experience.Frontiers in oncology · 2026Article
- Patterns of treatment failure and survival outcomes following definitive intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma: a single centre experience.Ecancermedicalscience · 2026Article
- Association of travel burden with colorectal cancer outcomes in resource-limited settings of Kashmir, India.Ecancermedicalscience · 2026Article
- Association between tumor volume changes during neoadjuvant chemoimmunotherapy and survival outcomes in esophageal squamous cell carcinoma: a multicenter study.Frontiers in immunology · 2026Article
- Spatially fractionated radiotherapy (Lattice SFRT) in the palliative treatment of locally advanced bulky unresectable head and neck cancer.Clinical and translational radiation oncology · 2024Article
- Optimal Time-to-Surgery Recommendations Based on Primary Tumor Volume Regression for Patients with Resectable Esophageal Cancer after Neoadjuvant Chemoradiotherapy: A Retrospective Study.Annals of surgical oncology · 2024Article
- Article
- Article
- Hypoxia in relationship to tumor volume using hypoxia PET-imaging in head & neck cancer - A scoping review.Clinical and translational radiation oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe prescribed radiation dose to patients with oropharyngeal squamous cell carcinoma (OPSCC) is standardized, even if the prognosis for individual patients may differ. Easy-at-hand pre-treatment risk stratification methods are valuable to individualize therapy. In the current study we assessed the prognostic impact of primary tumor volume for p16-positive and p16-negative tumors and in relationship to other prognostic factors for outcome in patients with OPSCC treated with primary radiation therapy (RT).
methodsFive hundred twenty-three OPSCC patients with p16-status treated with primary RT (68.0 Gy to 73.1 Gy in 7 weeks, or 68.0 Gy in 4.5 weeks), with or without concurrent chemotherapy, within three prospective trials were included in the study. Local failure (LF), progression free survival (PFS) and overall survival (OS) in relationship to the size of the primary gross tumor volume (GTV-T) and other prognostic factors were investigated. Efficiency of intensified RT (RT with total dose 73.1 Gy or given within 4.5 weeks) was analyzed in relationship to tumor volume.
resultsThe volume of GTV-T and p16-status were found to be the strongest prognostic markers for LF, PFS and OS. For p16-positive tumors, an increase in tumor volume had a significantly higher negative prognostic impact compared with p16-negative tumors. Within a T-classification, patients with a smaller tumor, compared with a larger tumor, had a better prognosis. The importance of tumor volume remained after adjusting for nodal status, age, performance status, smoking status, sex, and hemoglobin-level. The adjusted hazard ratio for OS per cm
conclusionsOutcome for patients with OPSCC treated with RT is largely determined by tumor volume, even when adjusting for other established prognostic factors. Tumor volume is significantly more influential for patients with p16-positive tumors. Patients with large tumor volumes might benefit by intensified RT to improve survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.